Update on Mayo Myriad Patent Eligibility From USPTO BCP Partnership Meeting

18 September 2014 PharmaPatents Blog

On September 17, 2014, the USPTO held the first “bicoastal” Biotechnology/Chemical/Pharmaceutical Customer Partnership meeting, with live participation from the USPTO’s main campus in Alexandria, VA and from San Jose University in San Jose, CA. The last item on the agenda was a panel on the Mayo-Myriad Guidance, so I joined the meeting by WebEx to hear what the panelists had to say about the current state of patent eligibility rejections and how to overcome them. 

June Cohan of the USPTO Office of Patent Legal Administration gave an overview of where the USPTO stands in its process of reviewing the public comments that were submitted in response to the March 4, 2014 Guidance and preparing revised Guidance. The good news is that, based on her comments, it sounds like the revised Guidance could be helpful, and could address at least the most surprising and problematic aspects of the original Guidance. The not-so-good news is that the revised Guidance may not be issued for another “month or so,” which means that we may have to respond to Office Actions that rejected claims under the original Guidance without the benefit of the revised Guidance.

When asked how Applicants should address rejections that are inconsistent with the USPTO’s current views (which appear to be more flexible than the Guidance has been applied by some examiners), USPTO representatives suggested that Applicants first speak with the Examiner, then speak with the Supervisor, then (if necessary) speak with a Group Director, or file a response explaining their positions in writing.

The stakeholder panelists discussed the impact of the Guidance on their ability to patent important technology, uneven application of the Guidance by different examiners, and the problematic uncertainty created by the Guidance.

Although the meeting did not reveal any sure-fire strategies for overcoming patent eligibility rejections, USPTO representatives agreed that the patent eligibility requirement should be a low hurdle, and that applicants should not have to unduly restrict the scope of their claims to satisfy § 101. Hopefully the revised Guidance will make these points clear to examiners and we can go back to worrying about novelty, non-obviousness, written description and enablement.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services